Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis
Abstract Background Psoriatic arthritis (PsA) patient data from two phase 3 secukinumab trials (FUTURE 1, 5) were analysed to quantify the prevalence and extent of pre-existing radiographic damage (RD) at baseline; investigate the association of RD with swollen/tender joint counts (SJC/TJC) at basel...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | Arthritis Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13075-022-02944-1 |
| _version_ | 1797973572936794112 |
|---|---|
| author | Philip Mease Désirée van der Heijde Bruce Kirkham Georg Schett Ana-Maria Orbai Christopher Ritchlin Joseph F. Merola Luminita Pricop David A. James Xuan Zhu Gregory Ligozio |
| author_facet | Philip Mease Désirée van der Heijde Bruce Kirkham Georg Schett Ana-Maria Orbai Christopher Ritchlin Joseph F. Merola Luminita Pricop David A. James Xuan Zhu Gregory Ligozio |
| author_sort | Philip Mease |
| collection | DOAJ |
| description | Abstract Background Psoriatic arthritis (PsA) patient data from two phase 3 secukinumab trials (FUTURE 1, 5) were analysed to quantify the prevalence and extent of pre-existing radiographic damage (RD) at baseline; investigate the association of RD with swollen/tender joint counts (SJC/TJC) at baseline; and investigate the extent to which RD at baseline correlated with response to secukinumab. Methods Pooled data (N = 1554) provided baseline radiographic bone erosion and joint space narrowing (JSN) scores at pre-specified locations per the van der Heijde-modified total Sharp score (vdH-mTSS) for PsA and swollen and tender joint scores in the same joints at multiple visits. Overall patient RD and individual joints RD bone erosion and JSN scores were assessed. The association between joint activity (tenderness, swelling) and vdH-mTSS was assessed at the overall patient-level and individual joint tender, swollen scores (yes/no) and RD joint JSN and bone erosion scores at the individual joint-level. Treatment response was assessed using SJC/TJC at weeks 16 and 52 and the proportion of patients achieving minimal disease activity (MDA) over all assessments within 1 year from FUTURE 5 alone. Results A substantial prevalence of pre-existing RD with higher prevalence of erosion than JSN was observed (86% and 60% of patients had positive erosion and JSN scores, respectively); higher RD prevalence was associated with longer time since PsA diagnosis. Joint activity was weakly associated with RD at baseline at the patient-level (Pearson’s coefficients: range 0.12–0.18), but strongly associated at the individual joint-level, with a higher probability of tender/swollen joints to associate with higher JSN/erosion scores: all 42 analysed joints showed statistical significance at the 0.05 level (unadjusted) for the relationship between joint tenderness (yes/no) and its JSN score, all but one for tenderness and bone erosion scores, and all but 2 for swollen and JSN scores and for swollen and bone erosion score. Secukinumab (150/300 mg), reduced TJC and SJC across all values of baseline erosion and JSN scores at weeks 16 and 52. Patients with higher levels of RD were less likely to achieve zero tender/zero swollen joint status and had lower chance of achieving MDA. Conclusions PsA patients showed substantial prevalence of RD at baseline that correlated with time since diagnosis, but patient’s individual joint activity was strongly associated with pre-existing RD at those joints. Patients with the highest RD at baseline had a reduced likelihood of achieving zero joint count status. |
| first_indexed | 2024-04-11T04:06:23Z |
| format | Article |
| id | doaj.art-88cfee0faae741c196f42420661bb5fc |
| institution | Directory Open Access Journal |
| issn | 1478-6362 |
| language | English |
| last_indexed | 2024-04-11T04:06:23Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Arthritis Research & Therapy |
| spelling | doaj.art-88cfee0faae741c196f42420661bb5fc2023-01-01T12:24:05ZengBMCArthritis Research & Therapy1478-63622022-12-0124111110.1186/s13075-022-02944-1Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritisPhilip Mease0Désirée van der Heijde1Bruce Kirkham2Georg Schett3Ana-Maria Orbai4Christopher Ritchlin5Joseph F. Merola6Luminita Pricop7David A. James8Xuan Zhu9Gregory Ligozio10Swedish Medical Centre, Providence St Joseph Health and University of WashingtonLeiden University Medical CentreGuy’s & St Thomas’ NHS Foundation TrustFriedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum ErlangenJohn Hopkins Arthritis CenterUniversity of RochesterBrigham and Women’s Hospital, Harvard Medical SchoolNovartis Pharmaceuticals CorporationNovartis Pharmaceuticals CorporationNovartis Pharmaceuticals CorporationNovartis Pharmaceuticals CorporationAbstract Background Psoriatic arthritis (PsA) patient data from two phase 3 secukinumab trials (FUTURE 1, 5) were analysed to quantify the prevalence and extent of pre-existing radiographic damage (RD) at baseline; investigate the association of RD with swollen/tender joint counts (SJC/TJC) at baseline; and investigate the extent to which RD at baseline correlated with response to secukinumab. Methods Pooled data (N = 1554) provided baseline radiographic bone erosion and joint space narrowing (JSN) scores at pre-specified locations per the van der Heijde-modified total Sharp score (vdH-mTSS) for PsA and swollen and tender joint scores in the same joints at multiple visits. Overall patient RD and individual joints RD bone erosion and JSN scores were assessed. The association between joint activity (tenderness, swelling) and vdH-mTSS was assessed at the overall patient-level and individual joint tender, swollen scores (yes/no) and RD joint JSN and bone erosion scores at the individual joint-level. Treatment response was assessed using SJC/TJC at weeks 16 and 52 and the proportion of patients achieving minimal disease activity (MDA) over all assessments within 1 year from FUTURE 5 alone. Results A substantial prevalence of pre-existing RD with higher prevalence of erosion than JSN was observed (86% and 60% of patients had positive erosion and JSN scores, respectively); higher RD prevalence was associated with longer time since PsA diagnosis. Joint activity was weakly associated with RD at baseline at the patient-level (Pearson’s coefficients: range 0.12–0.18), but strongly associated at the individual joint-level, with a higher probability of tender/swollen joints to associate with higher JSN/erosion scores: all 42 analysed joints showed statistical significance at the 0.05 level (unadjusted) for the relationship between joint tenderness (yes/no) and its JSN score, all but one for tenderness and bone erosion scores, and all but 2 for swollen and JSN scores and for swollen and bone erosion score. Secukinumab (150/300 mg), reduced TJC and SJC across all values of baseline erosion and JSN scores at weeks 16 and 52. Patients with higher levels of RD were less likely to achieve zero tender/zero swollen joint status and had lower chance of achieving MDA. Conclusions PsA patients showed substantial prevalence of RD at baseline that correlated with time since diagnosis, but patient’s individual joint activity was strongly associated with pre-existing RD at those joints. Patients with the highest RD at baseline had a reduced likelihood of achieving zero joint count status.https://doi.org/10.1186/s13075-022-02944-1Psoriatic arthritisRadiographic damageBone erosionJoint space narrowingMinimal disease activity |
| spellingShingle | Philip Mease Désirée van der Heijde Bruce Kirkham Georg Schett Ana-Maria Orbai Christopher Ritchlin Joseph F. Merola Luminita Pricop David A. James Xuan Zhu Gregory Ligozio Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis Arthritis Research & Therapy Psoriatic arthritis Radiographic damage Bone erosion Joint space narrowing Minimal disease activity |
| title | Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis |
| title_full | Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis |
| title_fullStr | Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis |
| title_full_unstemmed | Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis |
| title_short | Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis |
| title_sort | quantification of pre existing radiographic damage and its relationship with joint activity and long term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis |
| topic | Psoriatic arthritis Radiographic damage Bone erosion Joint space narrowing Minimal disease activity |
| url | https://doi.org/10.1186/s13075-022-02944-1 |
| work_keys_str_mv | AT philipmease quantificationofpreexistingradiographicdamageanditsrelationshipwithjointactivityandlongtermclinicaloutcomeswithsecukinumabtherapyinpatientswithpsoriaticarthritis AT desireevanderheijde quantificationofpreexistingradiographicdamageanditsrelationshipwithjointactivityandlongtermclinicaloutcomeswithsecukinumabtherapyinpatientswithpsoriaticarthritis AT brucekirkham quantificationofpreexistingradiographicdamageanditsrelationshipwithjointactivityandlongtermclinicaloutcomeswithsecukinumabtherapyinpatientswithpsoriaticarthritis AT georgschett quantificationofpreexistingradiographicdamageanditsrelationshipwithjointactivityandlongtermclinicaloutcomeswithsecukinumabtherapyinpatientswithpsoriaticarthritis AT anamariaorbai quantificationofpreexistingradiographicdamageanditsrelationshipwithjointactivityandlongtermclinicaloutcomeswithsecukinumabtherapyinpatientswithpsoriaticarthritis AT christopherritchlin quantificationofpreexistingradiographicdamageanditsrelationshipwithjointactivityandlongtermclinicaloutcomeswithsecukinumabtherapyinpatientswithpsoriaticarthritis AT josephfmerola quantificationofpreexistingradiographicdamageanditsrelationshipwithjointactivityandlongtermclinicaloutcomeswithsecukinumabtherapyinpatientswithpsoriaticarthritis AT luminitapricop quantificationofpreexistingradiographicdamageanditsrelationshipwithjointactivityandlongtermclinicaloutcomeswithsecukinumabtherapyinpatientswithpsoriaticarthritis AT davidajames quantificationofpreexistingradiographicdamageanditsrelationshipwithjointactivityandlongtermclinicaloutcomeswithsecukinumabtherapyinpatientswithpsoriaticarthritis AT xuanzhu quantificationofpreexistingradiographicdamageanditsrelationshipwithjointactivityandlongtermclinicaloutcomeswithsecukinumabtherapyinpatientswithpsoriaticarthritis AT gregoryligozio quantificationofpreexistingradiographicdamageanditsrelationshipwithjointactivityandlongtermclinicaloutcomeswithsecukinumabtherapyinpatientswithpsoriaticarthritis |